With the mental health crisis worsening in the United States, recent research explores novel treatments and underlying causes.

The mental health crisis in the United States has steadily been worsening over the past several years and was further exacerbated by the COVID-19 pandemic. Three in 10 adults in the country now report experiencing anxiety and depression, suicide deaths reached an all-time high in 2022, and more than 111,000 people died from a drug overdose in the 12-month period ending April 2023.1,2,3 In order to deal with the public health emergency, which impacts all segments of society, expanded access to services, more mental health professionals, and new forms of treatment are desperately needed.

Psilocybin Treatment for PTSD Shows Positive Topline Results in Phase 2 Study

A single dose of Compass Pathways’ investigational COMP360 was well tolerated and showed durable improvements in CAPS-5 and SDS total scores compared to baseline.

Check out this list of resources to share with patients who are experiencing mental health conditions.

Researchers Announce Positive Efficacy Results for Long-Acting Subcutaneous Olanzapine Injection

The drug, TEV-749, demonstrated statistically significant and clinically meaningful efficacy results.

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

For National Fentanyl Awareness Day, Drug Topics talked with Scott H. Silverman about how public health leaders can address the fentanyl crisis and the best ways to educate the public on the dangers of fentanyl use.

Psilocybin Treatment for PTSD Shows Positive Topline Results in Phase 2 Study

A single dose of Compass Pathways’ investigational COMP360 was well tolerated and showed durable improvements in CAPS-5 and SDS total scores compared to baseline.

Check out this list of resources to share with patients who are experiencing mental health conditions.

Researchers Announce Positive Efficacy Results for Long-Acting Subcutaneous Olanzapine Injection

The drug, TEV-749, demonstrated statistically significant and clinically meaningful efficacy results.

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

For National Fentanyl Awareness Day, Drug Topics talked with Scott H. Silverman about how public health leaders can address the fentanyl crisis and the best ways to educate the public on the dangers of fentanyl use.

By admin